Literature DB >> 9685871

Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium, USP.

A Leone-Bay1, D R Paton, B Variano, H Leipold, T Rivera, J Miura-Fraboni, R A Baughman, N Santiago.   

Abstract

Ten N-acylated, non-alpha-amino acids have been prepared as oral delivery agents and used to demonstrate the oral delivery of heparin in vivo in rats and primates. Following the oral administration of solutions containing a combination of heparin and a delivery agent to rats or primates, significant plasma heparin concentrations were evidenced by APTT and anti-Factor Xa assays. The estimated pharmacodynamic equivalence for an oral dosing solution containing heparin and a delivery agent is 39% in primates. In vitro experiments based on heparin affinity chromatography or heparin/methylene blue complexation were also performed to begin investigation of the mechanism by which these compounds facilitate heparin oral delivery. Results of in vitro studies suggest that absorption of the drug across the gastrointestinal membrane is the result of a non-covalent interaction between heparin and the delivery agent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685871     DOI: 10.1016/s0168-3659(97)00101-6

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  11 in total

1.  Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P.

Authors:  M Thanou; J C Verhoef; M T Nihot; J H Verheijden; H E Junginger
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 2.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.

Authors:  Aaron D Baldwin; Karyn G Robinson; Jaimee L Militar; Christopher D Derby; Kristi L Kiick; Robert E Akins
Journal:  J Biomed Mater Res A       Date:  2012-05-21       Impact factor: 4.396

4.  Anti-angiogenic poly-L-lysine dendrimer binds heparin and neutralizes its activity.

Authors:  Khuloud T Al-Jamal; Wafa T Al-Jamal; Kostas Kostarelos; John A Turton; Alexander T Florence
Journal:  Results Pharma Sci       Date:  2011-12-08

Review 5.  The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Authors:  Nusrat A Motlekar; Bi-Botti C Youan
Journal:  J Control Release       Date:  2006-06-14       Impact factor: 9.776

6.  Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin.

Authors:  Nusrat A Motlekar; Alessio Fasano; Mitchell S Wachtel; Bi-Botti C Youan
Journal:  J Drug Target       Date:  2006-06       Impact factor: 5.121

7.  Oral delivery of biologically active parathyroid hormone.

Authors:  A Leone-Bay; M Sato; D Paton; A H Hunt; D Sarubbi; M Carozza; J Chou; J McDonough; R A Baughman
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

8.  Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate.

Authors:  Dmitry Malkov; Huai-Zhen Wang; Steven Dinh; Isabel Gomez-Orellana
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

9.  Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.

Authors:  Yiwei Qi; Ganlin Zhao; Dongfang Liu; Zachary Shriver; Mallik Sundaram; Shiladitya Sengupta; Ganesh Venkataraman; Robert Langer; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-29       Impact factor: 11.205

10.  Oral heparin: status review.

Authors:  Ehud Arbit; Michael Goldberg; Isabel Gomez-Orellana; Shingai Majuru
Journal:  Thromb J       Date:  2006-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.